Takeda Faces Added Month Not Knowing Fate Of Actos In Europe
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical experienced a new setback for its Actos (pioglitazone) diabetes drug when European Union regulators postponed a decision of whether to allow it to remain on the market